RxDoctor Payments Data

Michele Martin Jones, MD

Family Medicine · Baltimore, MDNPI 1760557011

Payments from drug & device makers

$3,993in general payments, 2019–2025

Across 156 payments — averaging $25.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$707
  • GSK$387
  • Novo Nordisk$353
  • Amgen$315
  • Bayer$302
  • plus $866 from 13 others

What the payments were for

  • Food & beverage$3,985100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,993 in reported general payments places this provider in the 85th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$59,718
Medicare patients
88
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$54,868
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$35,619
JardianceEmpagliflozin29$30,536
EliquisApixaban13$13,452
TrulicityDulaglutide12$13,067
JanuviaSitagliptin Phosphate11$12,558
FarxigaDapagliflozin Propanediol14$10,093
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,883
Atorvastatin Calcium127$2,767
Ezetimibe27$2,052
Amlodipine Besylate123$1,470
Metoprolol Succinate60$1,162
Rosuvastatin Calcium26$876
Levothyroxine Sodium50$542
Lisinopril25$363

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$353$54,86857 claims
GSKTrelegy Ellipta$387$35,61939 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,063$18,97628 claims
PfizerEliquis$119$13,45213 claims
Lilly USA, LLCTrulicity$707$13,06712 claims
MerckJanuvia$122$12,55811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →